undamentalytics Newsletter

Kolchinsky Peter: insider trades

Director, 10% owner at 16 companies we cover. 16 open-market purchases and 7 sales not made under a pre-set plan, reported from October 16, 2015 to July 23, 2026.

Would copying Kolchinsky Peter’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 12 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on October 19, 2015 into $1,642 by November 2, 2026, −15.1% a year. The copy held shares only 65% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $50,021, +15.7% a year (the S&P 500 held throughout made $44,495, +14.5% a year). Beta against the index was 0.55. Twelve months after each report, the average purchase was −22.5% against the S&P 500 (median −32.6%), and 33% beat it. Measured from the trade date, the insider’s own timing, the average was −17.4%. After their sales, the shares moved −50.4% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201520172019202120232025 $50.0k$44.5k$1.6k
Copying Kolchinsky PeterS&P 500, same days investedS&P 500, held throughout $10,000 copying Kolchinsky Peter’s open-market purchases from October 19, 2015, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−15.1%
S&P 500, same days invested
+15.7% (held throughout +14.5%)
Time in shares
65%
Sharpe ratio (S&P 500)
−0.02 (0.73)
Biggest drop (S&P 500)
−97% (−34%)
Market sensitivity (beta)
0.55
Purchases copied
14

Trade by trade

Kolchinsky Peter: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 14 −8.4% −16.1% 29% 8 −0.07 0.95 No reliable evidence
Purchases, 6 months after the report 12 −17.8% −25.6% 33% 7 −0.31 0.77 No reliable evidence
Purchases, 12 months after the report 12 −22.5% −32.6% 33% 7 −0.34 0.74 No reliable evidence
Purchases, 12 months after the trade 12 −17.4% −28.9% 33% 7 −0.13 0.90 No reliable evidence
Sales, 3 months after the report 5 −7.5% −19.4% 60% 4 −0.04 0.97 No reliable evidence
Sales, 12 months after the report 2 −50.4% −50.4% 100% 2 — — Not enough years
Sales, 12 months after the trade 3 −43.2% −35.5% 100% 3 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Aclaris Therapeutics, Inc. ACRS —30October 16, 2015January 13, 2016
Kala BIO, Inc. KALA —11March 13, 2020May 26, 2022
Fulcrum Therapeutics, Inc. FULC —20December 21, 2022December 29, 2022
Climb Bio, Inc. CLYM —20July 1, 2024December 15, 2025
Vor Biopharma Inc. VOR —02October 30, 2025April 6, 2026
Artiva Biotherapeutics, Inc. ARTV —20June 16, 2026July 23, 2026
TG Therapeutics, Inc. TGTX —01September 11, 2020September 11, 2020
Phathom Pharmaceuticals, Inc. PHAT —01March 15, 2021March 15, 2021
Solid Biosciences Inc. SLDB —10March 23, 2021March 23, 2021
Enliven Therapeutics, Inc. ELVN —10October 19, 2022October 19, 2022
Wave Life Sciences, Inc. WVE —10December 13, 2023December 13, 2023
Pepgen Inc. PEPG —10February 13, 2024February 13, 2024
Janux Therapeutics, Inc. JANX —10October 22, 2024October 22, 2024
Tyra Biosciences, Inc. TYRA —10June 6, 2025June 6, 2025
Sionna Therapeutics, Inc. SION —01November 24, 2025November 24, 2025
Werewolf Therapeutics, Inc. HOWL —01June 11, 2026June 11, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
July 23, 2026July 21, 2026 ARTV Purchase $2,583,314 −41.8%not yetnot yet
June 16, 2026June 12, 2026 ARTV Purchase $4,599,903 −18.3%not yetnot yet
June 11, 2026June 9, 2026 HOWL Sale $253,569 not yetnot yetnot yet
April 6, 2026April 2, 2026 VOR Sale $14,518,963 +7.2%not yetnot yet
December 15, 2025December 11, 2025 CLYM Purchase $754,737 not yetnot yetnot yet
November 24, 2025November 20, 2025 SION Sale $1,200,704 −19.4%not yetnot yet
October 30, 2025October 28, 2025 VOR Sale $10,368,938 −48.2%not yet−35.5%
June 6, 2025June 4, 2025 TYRA Purchase $11,751,304 +6.4%+125.4%+134.5%
October 22, 2024October 18, 2024 JANX Purchase $53,700,000 −19.9%−67.1%−63.0%
July 1, 2024June 27, 2024 CLYM Purchase $49,952,817 −28.1%−96.0%−98.7%
February 13, 2024February 9, 2024 PEPG Purchase $27,212,790 −4.4%−113.9%−113.6%
December 13, 2023December 11, 2023 WVE Purchase $5,000,000 not yetnot yetnot yet
December 29, 2022December 27, 2022 FULC Purchase $24,493 −69.8%−24.7%−13.3%
December 21, 2022December 19, 2022 FULC Purchase $582,843 −54.5%−20.9%−32.0%
October 19, 2022October 17, 2022 ELVN Purchase $1,861,376 −10.1%−41.6%−25.7%
May 26, 2022May 26, 2022 KALA Sale $362,047 not yetnot yetnot yet
March 23, 2021March 19, 2021 SLDB Purchase $12,688,439 −36.8%−92.6%−91.2%
March 15, 2021March 11, 2021 PHAT Sale $31,062,500 −31.6%−82.8%−78.5%
September 11, 2020September 9, 2020 TGTX Sale $4,093,182 +54.8%−18.0%−15.5%
March 13, 2020March 13, 2020 KALA Purchase $49,999,995 +82.6%−40.4%−33.6%
January 13, 2016January 11, 2016 ACRS Purchase $298,749 −14.0%+14.9%+30.1%
October 21, 2015October 19, 2015 ACRS Purchase $521,188 +47.0%+47.2%+39.9%
October 16, 2015October 14, 2015 ACRS Purchase $601,951 +44.7%+39.9%+57.8%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Kolchinsky Peter traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.